# REVOLVE SYSTEM FOR USE IN YOUR PLASTIC AND RECONSTRUCTIVE BREAST SURGERIES

Allergan's autologous fat-processing system

Functional for small to large volume fat processing, from 100 to 350 mL of adipose per harvest.<sup>1</sup>







## WHAT IS THE REVOLVE™ SYSTEM?

- A **sterile, single-use disposable** tissue canister used for **harvesting**, **filtering, separating, concentrating** and **transferring** autologous tissue components for reintroduction to the same patient during a single surgical procedure<sup>1</sup>
- A **streamlined system** designed to simplify fat processing for use in fat-transfer procedures<sup>1</sup>

### Designed to be user-friendly, efficient and cost-effective<sup>1-3</sup>

- A **time-efficient system** shown to have processed large volumes of fat in approximately **10 minutes**<sup>2</sup>
  - Only requires a few steps to process large quantities of adipose tissue<sup>1,4</sup>
  - Decreased operative time can lead to potential cost savings compared to centrifugation<sup>3</sup>
- Proprietary **collagen string catcher designed to minimize clogging** within syringe tips to effectively enhance procedural speed.<sup>1,2</sup>



Image courtesy of Allergan Inc.

The REVOLVE<sup>™</sup> System is a relatively simple device which can be used in a variety of surgical settings.<sup>3,5</sup>

# WHAT WERE THE RESULTS OF FAT PROCESSING USING THE REVOLVE™ SYSTEM?

## **Preclinical results**

- Compared to centrifugation, decantation or PureGraft<sup>™</sup>, tissues processed with the REVOLVE<sup>™</sup> System contained:
  - Greater numbers of viable fat cells<sup>6</sup>
  - Higher fat cell activity<sup>6</sup>
  - Greater numbers of stromal vascular fraction cells (SVF)<sup>6</sup>
  - Greater numbers of colony-forming units (CFUs)<sup>6</sup>
- The tissue retained within the waste contained insignificant amounts of both fat cells and SVF cells<sup>6</sup>
- Compared to centrifugation and decantation, the REVOLVE<sup>™</sup> System processed tissue contained:
  - Low amounts of extraneous fluid<sup>2,6</sup>
  - Significantly less blood cell debris and free oil<sup>2</sup>
  - Low hemoglobin (RBC) concentration<sup>2</sup>
- The REVOLVE<sup>™</sup> System meets product endotoxin requirements<sup>7</sup>
- In a rat model, **percent fat retention** from REVOLVE<sup>TM</sup> samples was significantly higher than that from decanted samples (P < 0.05) and was not significantly different to that from centrifuged samples<sup>2</sup>
  - $\circ$  73.2% ± 14.7% (n = 79) for the REVOLVE<sup>™</sup> System<sup>2</sup>
  - $\circ$  67.7% ± 16.9% (n = 80) for centrifugation<sup>2</sup>
  - $\circ$  37.5% ± 13.3% (n = 77) for decantation<sup>2</sup>
- In the same rat model, the REVOLVE<sup>™</sup> System lead to reliable and reproducible fat graft retention<sup>2</sup>

## **Clinical results**

- Fat grafting helped **improve aesthetic results** through the correction of **volume** and **shape**, and has been shown to **contour deformities** in reconstructed breasts<sup>8</sup>
- Patients who had fat grafting with the REVOLVE<sup>™</sup> System (compared to centrifugation) **required less subsequent surgeries** and fewer patients experienced nodule or cyst formation<sup>3</sup>

The REVOLVE<sup>™</sup> System can produce physiologically compatible, preinjection fat with reduced contaminants and free oil in conjunction with high fat content compared to centrifugation and decantation methods.<sup>2</sup>

## **ORDERING INFORMATION**

## **REVOLVE™** System

The autologous fat-processing system for use in breast reconstruction procedures.<sup>1</sup>

- The minimum tissue harvest volume is **100 mL** and the maximum tissue harvest volume is **350 mL**<sup>1</sup>
- Processing equipment is supplied in each single-use, sterile pack<sup>1</sup>









Temperature Strip

Disposable Adapter

Images courtesy of Allergan Inc.

	Product Code <sup>9</sup>	Quantity
REVOLVE™ System		
	RV0001WW	1 Unit Pack

## **Ordering:**

To place an order, please call GD Medical at +31(0)40 - 3031 090 or visit gdmedical.nl.

Please refer to the package insert supplied with each device for indications, contraindications, warnings, instructions for use, limited warranty, and patient, physician, and manufacturer information.

#### Storage:

REVOLVE<sup>™</sup> products must be stored according to the product label.

#### Adverse Events and Reporting:

Some common adverse effects associated with use of the REVOLVE<sup>™</sup> System and/or autologous fat transfer procedures are asymmetry, over- and/or under-correction of the treatment site, tissue lumps, bleeding, scarring, fat necrosis, cyst formation, allergic reaction, and infection and inflammation of various levels. If an unanticipated event occurs, alteration of surgical plan may be necessary at the surgeon's discretion.<sup>1</sup>

References:

1. Altergan Inc. REVOLVE<sup>™</sup> Advanced Adipose System Instructions for Use. 2018. 2. Ansorge H, Garza JR, McCormack MC, Leamy P, Roesch S, Barere A, et al. Autologous fat processing via the Revolve system: quality and quantity of fat retention evaluated in an animal model. Aesthet Surg J. 2014;34(3):458-47. S. Gabriel A, Maxwell CP, Griffin L, Champaneria MC, Parek M, Macarios D. Ac comparison of two fat grafting methods on operating room efficiency and costs. Aesthet Surg J. 2016;37(2):161-8. 4. Altergan Inc. Data on File: End User Evaluation – REVOLVE versus LipiVage and PureGraft, INT/0459/2018. 5. Brzezienski MA, Jarrell IV A Autologous fat grafting to the breast using REVOLVE system to reduce clinical costs Ann Plast Surg 2016;77(3):286-9. 6. Altergan Inc. Data on File: Fat Processing Using REVOLVE™ System in Comparison with Other Processing Methods, INT/0076/2018. 7. Altergan Inc. Data on File: REVOLVE System Endotoxin Detection Testing, INT/0474/2018. 8. Gabriel A, Champaneria MC, Maxwell GP Fat grafting and breast reconstruction: tips for ensuring predictability. ISIA05232. Different MCC Leamer Structure LifeCeII Portfolio – Product Dptions, INT/0217018.



INT/0195/2018 Date of preparation: September 2018



